Evidence map›Paper›PMID 38441016›Full record

ArticleRecent advances in anti-infective drug discovery2025

Seroepidemiology of

Atefeh Oveisipour, Maryam Hataminejad, Bahman Fouladi, Hakim Azizi

Abstract read
PubMed Publisher
In one paragraph

Article in Recent advances in anti-infective drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Atefeh OveisipourDepartment of Parasitology and Mycology, School of Medicine Zabol University of Medical Sciences, Zabol, Iran.
Maryam HataminejadDepartment of Medical Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0000-0002-9094-5424
Bahman FouladiDepartment of Parasitology and Mycology, School of Medicine Zabol University of Medical Sciences, Zabol, Iran.ORCID 0000-0002-9848-6242
Hakim AziziDepartment of Parasitology and Mycology, School of Medicine Zabol University of Medical Sciences, Zabol, Iran.ORCID 0000-0003-1095-1806
Zabol University of Medical Sciences · IRMazandaran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecent research has been concentrated on investigating the involvement of

methodsA case-control study was conducted between December 2021 and September 2022. The study included 225 patients diagnosed with NAFLD as the case group and 225 healthy blood donors as the control group. The controls were selected from the same region and were matched with the patients based on gender and age. We collected serum samples from all patients and utilized an enzyme-linked immunosorbent assay to analyze them for the existence of anti-

resultsThe prevalence of anti-

conclusionThe findings of this study indicate a high seroprevalence of

Indexed as

Non-alcoholic Fatty Liver DiseaseToxoplasmaToxoplasmosisAdultAgedAntibodies, ProtozoanBiomarkersCase-Control StudiesFemaleHumansImmunoglobulin GIranMaleMiddle AgedPrevalenceSeroepidemiologic StudiesAntibodies, ProtozoanBiomarkersImmunoglobulin GIgG antibodies.Liver diseasenon-alcoholic fatty liverseroepidemiologyseroprevalenceToxoplasma gondii

Identifiers

PMID38441016
OpenAlexW4392471519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.